查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2104981

新抗原癌症疫苗市場規模、佔有率和趨勢分析：按疫苗類型、給藥途徑、應用和最終用戶分類 - 全球機會分析和行業預測（2026-2036 年）

Neoantigen Cancer Vaccine Market Size, Share & Trends Analysis by Vaccine Type, Delivery Modality, Application, and End User - Global Opportunity Analysis & Industry Forecast (2026-2036)
出版日期: | 出版商: Meticulous Research | 英文 289 Pages | 商品交期: 5-7個工作天內

價格
簡介目錄

全球新抗原癌症疫苗市場預計在2025年達到9億美元，2026年成長至14億美元，到2036年達到128億美元，預測期內複合年成長率（CAGR）為24.6%。本報告透過分析個人化腫瘤學、癌症免疫療法、基因測序技術、基於人工智慧（AI）的新抗原預測平台、疫苗研發技術、臨床管線拓展、競爭策略、疫苗類型、技術平台、給藥方法、臨床階段、應用、終端用戶以及各地區未來成長機會等方面的最新進展，對全球市場進行了全面評估。

新抗原癌症疫苗代表了一種新一代免疫療法，旨在刺激免疫系統對抗僅存在於癌細胞而非正常組織中的腫瘤特異性突變。與針對通用腫瘤相關抗原的傳統癌症疫苗不同，新抗原疫苗利用患者特異性的腫瘤突變來誘導高度標靶化的免疫反應，同時最大限度地降低自體免疫反應的風險。這些疫苗的研發採用了先進的基因測序、生物資訊分析和計算預測工具，以識別能夠活化T細胞反應攻擊癌細胞的腫瘤特異性新抗原。

由於癌症發病率上升、對個人化癌症治療的需求不斷成長、次世代定序（NGS）技術的進步、精準醫療的擴展以及對腫瘤免疫學研究投入的增加，市場正經歷著顯著成長。個人化新抗原疫苗候選藥物的臨床進展增強了人們對這種治療方法的信心，並鼓勵製藥公司、生物技術公司和研究機構擴大其癌症疫苗的研發計畫。

技術進步正在改變新抗原癌症疫苗生態系統，提升疫苗設計、生產速度和治療個人化程度。 mRNA疫苗平台、人工智慧驅動的新抗原預測演算法、基因測序、計算免疫學、脂質奈米顆粒（LNP）遞送系統以及自動化疫苗生產技術的創新，使得個人化癌症疫苗的識別和開發更加高效。基於mRNA的平台因其快速生產能力、編碼多種新抗原的能力以及誘導強效免疫反應的潛力而廣泛應用。

對聯合治療的日益重視為新抗原癌症疫苗創造了更多機會。這些疫苗正與免疫查核點抑制劑和其他免疫療法合併使用進行評估，以增強抗腫瘤反應並改善治療效果。將新抗原疫苗與查核點抑制劑合併使用的臨床計畫正在黑色素瘤、肺癌、大腸直腸癌和其他固體癌領域不斷擴展。

此外，定序技術和計算工具的進步，使得更快、更準確地識別患者特異性新抗原成為可能，這也對市場產生了積極影響。人工智慧和機器學習的整合使研究人員能夠優先篩選有前景的新抗原候選物，最佳化疫苗設計，並縮短研發週期。

儘管市場具有巨大的成長潛力，但也面臨著許多挑戰，例如複雜的個人化生產流程、高昂的研發成本、繁瑣的監管規定、個人化療法擴充性的局限性，以及提高新抗原預測準確性的迫切需求。各公司正透過標準化生產流程、共用的新抗原方法、先進的計算平台和高度擴充性的基於mRNA的技術來應對這些挑戰。

本報告透過分析市場動態、技術進步、競爭格局和新興機遇，對全球新抗原癌症疫苗市場進行了全面評估。該研究考察了關鍵行業趨勢、臨床開發、戰略夥伴關係、合作夥伴關係、併購、產品創新以及主要市場參與企業採取的競爭策略，為製藥公司、生物技術公司、投資者、醫療保健提供者、研究機構以及在全球癌症免疫治療生態系統中運營的其他相關人員提供了切實可行的見解。

市場動態

由於對個人化癌症治療的需求不斷成長、癌症免疫療法投資增加以及腫瘤特異性疫苗療法的臨床療效日益提高，新抗原癌症疫苗市場正在擴張。基因測序和計算生物學的進步使研究人員能夠識別患者特異性的癌症突變並開發標靶免疫療法。

技術創新仍是疫苗研發的主要成長要素，mRNA平台、人工智慧驅動的新抗原預測、先進的遞送系統和自動化生產解決方案等都提高了疫苗研發的效率。然而，個人化生產的複雜性、製造成本、監管要求以及治療的可及性等問題仍然影響著疫苗的市場滲透率。

預計在預測期內，製藥公司加大投資、臨床試驗增多、固體癌適應症擴大以及生物技術公司與研究機構加強合作，將為市場創造巨大的成長機會。

細分市場分析

本報告從疫苗類型、技術平台、給藥方法、臨床階段、適應症、最終用戶和地區等方面對新抗原癌症疫苗市場進行了全面分析，幫助相關人員識別高成長細分市場和新興商機。

目錄

第1章：引言

第2章：調查方法

第3章執行摘要

第4章 市場概覽

  • 市場動態
    • 促進因素
      • 個人化癌症免疫療法的廣泛應用
      • 基因組定序技術的進步
      • 全球癌症發生率上升
      • 一系列豐富的腫瘤新抗原候選疫苗
    • 抑制因子
      • 研發個人化疫苗高成本
      • 複雜的製造和物流
      • 有限商業批准
    • 機會
      • 合併查核點抑制劑聯合治療
      • 利用人工智慧進行新抗原預測的進展
      • mRNA疫苗平台的擴展
      • 臨床試驗的成長
    • 任務
      • 法規的複雜性
      • 患者反應的差異
  • 科技趨勢
    • 基於mRNA的新抗原疫苗
    • 基於胜肽的疫苗
    • DNA疫苗
    • 利用病毒載體的疫苗
    • 基於樹突狀細胞的疫苗
    • 人工智慧和生物資訊學在新抗原辨識的應用
  • 新抗原癌症疫苗生態系統
    • 生物製藥公司
    • 基因組定序服務供應商
    • CRO/CDMO
    • 研究機構
    • 醫療服務提供方
  • 價值鏈分析
    • 腫瘤樣本採集
    • 基因測序與分析
    • 新抗原的鑑定與選擇
    • 疫苗設計與生產
    • 臨床管理
  • 監理情勢
    • FDA/EMA 指南
    • 臨床試驗相關規定
    • 個人化醫療的法律規範
  • 產業趨勢
    • mRNA癌症疫苗的興起
    • 加強製藥公司與科技公司的合作
    • 個人化癌症醫學的發展
    • 將人工智慧融入疫苗設計
  • 成本和定價分析
    • 每位患者的成本
    • 製造成本分析
    • 與還款相關的問題

第5章：新抗原癌症疫苗市場：依疫苗類型分類

  • 個人化
  • 共用類型

第6章：新抗原癌症疫苗市場：依技術平台分類

  • 藥效疫苗
  • 胜肽疫苗
  • DNA疫苗
  • 病毒載體疫苗
  • 樹突細胞疫苗

第7章 新抗原癌症疫苗市場：依給藥途徑分類

  • 注射
  • 皮內給藥
  • 其他

第8章：新抗原癌症疫苗市場：依臨床階段分類

  • 臨床前階段
  • 第一階段
  • 第二階段
  • 第三階段

第9章：新抗原癌症疫苗市場：依應用領域分類

  • 固體癌
    • 肺癌
    • 黑色素瘤
    • 乳癌
    • 結腸癌
    • 其他
  • 血癌
    • 白血病
    • 淋巴瘤
    • 多發性骨髓瘤
  • 聯合治療

第10章：新抗原癌症疫苗市場：依最終用戶分類

  • 醫院及癌症治療中心
  • 研究機構
  • 生物製藥公司

第11章：新抗原癌症疫苗市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 瑞士
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 新加坡
    • 其他亞太國家
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家
  • 中東和非洲
    • UAE
    • 沙烏地阿拉伯
    • 南非
    • 其他中東和非洲國家

第12章 競爭格局

  • 關鍵成長策略
  • 競爭性標竿分析
  • 競爭對手儀錶板
    • 產業領導者
    • 市場差異化因素
    • 新興企業
  • 市場排名/定位分析

第13章：公司簡介

  • Moderna, Inc.
  • BioNTech SE
  • Genentech（Roche）
  • Gritstone bio, Inc.
  • Neon Therapeutics
  • CureVac NV
  • AstraZeneca plc
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Immatics NV
  • ISA Pharmaceuticals BV
  • Vaccibody AS
  • Nouscom AG
  • Genocea Biosciences
  • Advaxis Inc.

第14章附錄

簡介目錄
Product Code: MRHC - 1041979

The global Neoantigen Cancer Vaccine Market was valued at USD 0.9 billion in 2025 and is projected to reach USD 12.8 billion by 2036 from an estimated USD 1.4 billion in 2026, registering a CAGR of 24.6% during the forecast period. The report provides a comprehensive assessment of the global market by analyzing advancements in personalized oncology, cancer immunotherapy, genomic sequencing technologies, artificial intelligence (AI)-based neoantigen prediction platforms, vaccine development technologies, clinical pipeline expansion, competitive strategies, and future growth opportunities across vaccine types, technology platforms, delivery modalities, clinical stages, applications, end users, and geographic regions.

Neoantigen cancer vaccines represent a next-generation immunotherapy approach designed to stimulate the immune system against tumor-specific mutations that are present only in cancer cells and absent from healthy tissues. Unlike conventional cancer vaccines targeting shared tumor-associated antigens, neoantigen vaccines leverage patient-specific tumor mutations to generate highly targeted immune responses while minimizing the risk of autoimmune reactions. These vaccines are developed using advanced genomic sequencing, bioinformatics analysis, and computational prediction tools to identify tumor-specific neoantigens capable of activating cancer-fighting T-cell responses.

The market is witnessing significant growth due to increasing cancer incidence, rising demand for personalized cancer therapies, advancements in next-generation sequencing (NGS), growing adoption of precision medicine, and increasing investments in immuno-oncology research. The clinical progress of personalized neoantigen vaccine candidates has strengthened confidence in this therapeutic approach and encouraged pharmaceutical companies, biotechnology firms, and research organizations to expand their oncology vaccine development programs.

Technological advancements are transforming the neoantigen cancer vaccine ecosystem by improving vaccine design, manufacturing speed, and treatment personalization. Innovations in mRNA vaccine platforms, AI-driven neoantigen prediction algorithms, genomic sequencing, computational immunology, lipid nanoparticle (LNP) delivery systems, and automated vaccine manufacturing technologies are enabling more efficient identification and development of individualized cancer vaccines. mRNA-based platforms are gaining strong adoption due to their rapid manufacturing capabilities, ability to encode multiple neoantigens, and demonstrated potential in generating robust immune responses.

The increasing focus on combination therapies is creating additional opportunities for neoantigen cancer vaccines. These vaccines are being evaluated alongside immune checkpoint inhibitors and other immunotherapies to enhance anti-tumor responses and improve treatment outcomes. Clinical programs combining neoantigen vaccines with checkpoint inhibitors are expanding across melanoma, lung cancer, colorectal cancer, and other solid tumors.

The market is also benefiting from improvements in sequencing technologies and computational tools that enable faster and more accurate identification of patient-specific neoantigens. The integration of AI and machine learning is helping researchers prioritize promising neoantigen candidates, optimize vaccine design, and reduce development timelines.

Despite strong growth potential, the market faces challenges including complex personalized manufacturing processes, high development costs, regulatory complexities, limited scalability of individualized therapies, and the need for robust neoantigen prediction accuracy. Companies are addressing these challenges through standardized manufacturing workflows, shared neoantigen approaches, advanced computational platforms, and scalable mRNA-based technologies.

This report provides a comprehensive assessment of the global neoantigen cancer vaccine market by analyzing market dynamics, technology advancements, competitive landscape, and emerging opportunities. The study evaluates major industry trends, clinical developments, strategic collaborations, partnerships, mergers and acquisitions, product innovations, and competitive strategies adopted by leading market participants to provide actionable insights for pharmaceutical companies, biotechnology firms, investors, healthcare providers, research institutions, and other stakeholders operating in the global cancer immunotherapy ecosystem.

Market Dynamics

The neoantigen cancer vaccine market is expanding due to increasing demand for personalized oncology treatments, rising investments in cancer immunotherapy, and growing clinical validation of tumor-specific vaccine approaches. Advances in genomic sequencing and computational biology are enabling researchers to identify patient-specific cancer mutations and develop targeted immune therapies.

Technological innovation remains a major growth driver, with mRNA platforms, AI-based neoantigen prediction, advanced delivery systems, and automated manufacturing solutions improving vaccine development efficiency. However, challenges related to personalized production complexity, manufacturing costs, regulatory requirements, and treatment accessibility continue to influence market adoption.

Growing investments by pharmaceutical companies, increasing clinical trials, expanding applications across solid tumors, and rising collaborations between biotechnology companies and research institutions are expected to create significant opportunities for market growth during the forecast period

Segment Analysis

The report provides an extensive analysis of the neoantigen cancer vaccine market across vaccine type, technology platform, delivery modality, clinical stage, application, end user, and geography, enabling stakeholders to identify high-growth segments and emerging business opportunities.

Based on vaccine type, the market is segmented into personalized neoantigen vaccines and shared neoantigen vaccines.

Personalized neoantigen vaccines represent the leading segment due to their ability to generate patient-specific immune responses by targeting unique mutations identified within individual tumors. Increasing adoption of precision oncology approaches, advancements in next-generation sequencing (NGS), and improvements in computational neoantigen prediction are supporting the growth of personalized vaccine development. These vaccines are being extensively evaluated in clinical trials for melanoma, lung cancer, colorectal cancer, and other solid tumors.

Shared neoantigen vaccines are expected to witness increasing adoption due to their potential for broader patient applicability and improved scalability compared with fully individualized approaches. By targeting commonly occurring tumor mutations across patient populations, shared neoantigen vaccines may help overcome manufacturing complexity and reduce production timelines.

Based on technology platform, the market is analyzed across mRNA-based vaccines, peptide-based vaccines, DNA-based vaccines, viral vector-based vaccines, and dendritic cell-based vaccines.

mRNA-based vaccines are expected to account for a significant share of the market due to their rapid design capabilities, manufacturing flexibility, and ability to encode multiple neoantigens within a single vaccine construct. The success of mRNA technologies in infectious disease applications has accelerated investments in oncology applications, including personalized cancer vaccines.

Peptide-based vaccines continue to represent an important technology segment due to their established development pathways, favorable safety profiles, and ability to induce targeted immune responses. Advances in peptide design and antigen selection are improving their therapeutic potential.

Viral vector-based and dendritic cell-based platforms are also being explored due to their strong immunogenicity and ability to activate cellular immune responses. These platforms are being evaluated in combination with other immunotherapies to enhance anti-tumor activity.

Based on delivery modality, the market is segmented into in vivo delivery and ex vivo delivery approaches.

In vivo delivery approaches are gaining attention due to their potential to simplify vaccine administration and improve scalability. Advances in lipid nanoparticles and other delivery technologies are supporting the development of efficient methods for delivering neoantigen vaccine components directly into patients.

Ex vivo approaches remain important for personalized vaccine development, particularly for platforms involving patient-derived immune cells or specialized antigen-presenting cell technologies.

Based on clinical stage, the market is analyzed across preclinical, Phase I, Phase II, Phase III, and commercial stages.

Phase II clinical-stage programs represent a significant segment due to increasing transition of neoantigen vaccine candidates from early safety studies toward efficacy evaluation. Growing clinical evidence demonstrating immune activation and potential therapeutic benefits is encouraging further investment.

Based on application, the market is evaluated across melanoma, lung cancer, colorectal cancer, breast cancer, and other solid tumors.

Melanoma represents a major application segment due to high mutation rates associated with the disease and strong responsiveness to immunotherapy approaches. Neoantigen vaccines are being extensively investigated in melanoma treatment, often in combination with immune checkpoint inhibitors.

Lung cancer and colorectal cancer are expected to witness significant growth due to increasing research focused on developing personalized immunotherapies for patients with high unmet medical needs.

Based on end user, the market is segmented into pharmaceutical and biotechnology companies, academic and research institutions, hospitals and cancer centers, and contract research organizations (CROs).

Pharmaceutical and biotechnology companies represent the leading end-user segment due to significant investments in oncology pipelines, clinical trials, and commercialization strategies. CROs and research institutions are also gaining importance by supporting clinical development, genomic analysis, and vaccine optimization activities.

Regional Analysis

The report provides a detailed assessment of market performance across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. Regional analysis considers cancer burden, biotechnology investments, genomic research capabilities, clinical trial activity, healthcare infrastructure, and adoption of precision medicine technologies.

North America dominates the neoantigen cancer vaccine market due to strong oncology research infrastructure, presence of leading biotechnology companies, significant investments in personalized medicine, and a high number of clinical trials. The region benefits from advanced genomic sequencing capabilities and strong collaborations between pharmaceutical companies and research institutions.

Europe represents a significant market supported by growing investments in cancer immunotherapy, expanding precision medicine initiatives, and increasing research collaborations focused on personalized cancer vaccines.

Asia-Pacific is expected to register strong growth due to rising cancer incidence, increasing biotechnology investments, expanding clinical research capabilities, and growing adoption of advanced genomic technologies. Countries such as China, Japan, South Korea, and Singapore are strengthening their cancer immunotherapy ecosystems.

Latin America and the Middle East & Africa are expected to present emerging opportunities due to improving healthcare infrastructure, increasing cancer research initiatives, and growing access to advanced oncology treatments.

Competitive Landscape

The report presents a detailed evaluation of the competitive landscape, offering valuable insights into the strategic positioning of major industry participants. It examines company portfolios, neoantigen discovery platforms, vaccine development capabilities, technology platforms, clinical pipelines, manufacturing expertise, business strategies, partnerships, collaborations, mergers and acquisitions, product developments, and other significant corporate initiatives shaping the competitive environment.

Company benchmarking enables stakeholders to compare market participants based on their neoantigen identification technologies, genomic sequencing capabilities, artificial intelligence (AI)-based prediction platforms, vaccine design approaches, mRNA and peptide-based vaccine expertise, clinical development progress, manufacturing capabilities, regulatory experience, geographic presence, and competitive strengths. The report also evaluates the evolving competitive landscape driven by advancements in precision oncology, next-generation sequencing, computational immunology, AI-enabled antigen prediction, personalized vaccine manufacturing, and combination immunotherapy approaches.

As pharmaceutical and biotechnology companies increasingly focus on personalized cancer treatments, market participants are investing in innovative neoantigen discovery and vaccine development platforms to improve treatment precision, shorten manufacturing timelines, and enhance therapeutic outcomes. Companies are strengthening their positions through proprietary technologies, strategic collaborations with academic institutions and research organizations, licensing agreements, clinical trial advancements, and expansion of oncology immunotherapy pipelines.

Continuous innovation aimed at improving neoantigen prediction accuracy, optimizing vaccine formulations, enhancing immune response, reducing manufacturing complexity, and developing scalable production approaches is expected to drive competitive differentiation across the market. Leading companies are also focusing on integrated solutions combining genomic analysis, computational modeling, vaccine design, manufacturing, and clinical development support to accelerate the translation of neoantigen vaccines from research platforms to commercial therapies.

Strategic partnerships between biotechnology companies, pharmaceutical organizations, technology providers, and research institutions are becoming increasingly important for advancing personalized cancer vaccine development. Companies are investing in AI-driven platforms, automated manufacturing technologies, and next-generation delivery systems to address challenges associated with individualized vaccine production and broader clinical adoption.

Key companies profiled in the report include BioNTech SE, Moderna, Inc., Gritstone bio, Inc., Genentech (Roche Group), Nouscom AG, ISA Pharmaceuticals B.V., Evaxion Biotech A/S, BrightPath Biotherapeutics Co., Ltd., Neon Therapeutics (acquired by BioNTech), and Immatics N.V.

How This Report Helps

  • Provides reliable market size estimates and long-term growth forecasts.
  • Evaluates key market drivers, restraints, opportunities, challenges, and emerging neoantigen vaccine trends.
  • Identifies high-growth vaccine type, technology platform, delivery modality, clinical stage, application, end-user, and regional segments.
  • Assesses innovation trends across personalized cancer vaccines, mRNA platforms, AI-based neoantigen prediction, and precision oncology.
  • Benchmarks leading companies based on technology capabilities, clinical pipelines, strategic initiatives, and competitive positioning.
  • Supports investment planning, partnership evaluation, clinical development strategies, technology assessment, and market entry decisions.
  • Provides actionable insights for pharmaceutical companies, biotechnology firms, research organizations, investors, healthcare providers, and other stakeholders operating in the global cancer immunotherapy ecosystem.

Key Questions Answered

  • What is the current size of the global neoantigen cancer vaccine market, and what is its projected growth through 2036?
  • Which factors are driving, restraining, and influencing market growth?
  • What opportunities and challenges are expected to shape the industry during the forecast period?
  • Which vaccine types, technology platforms, delivery modalities, applications, end users, and regions are expected to witness the strongest growth?
  • Which regions offer the most attractive opportunities for neoantigen cancer vaccine development and adoption?
  • Who are the leading companies operating in the market, and how are they strengthening their competitive positions?
  • What recent clinical advancements, technology developments, partnerships, mergers and acquisitions, and strategic initiatives are influencing the competitive landscape?
  • How can stakeholders leverage market intelligence from this report to support strategic planning, investment decisions, clinical development, and growth across the global neoantigen cancer vaccine market?

TABLE OF CONTENTS

1. Introduction

  • 1.1 Market Definition
  • 1.2 Scope
  • 1.3 Market Ecosystem
  • 1.4 Currency and Limitations
    • 1.4.1 Currency
    • 1.4.2 Limitations
  • 1.5 Key Stakeholders

2. Research Methodology

  • 2.1 Research Approach
  • 2.2 Data Collection & Validation
    • 2.2.1 Secondary Research
    • 2.2.2 Primary Research (Oncologists, Biopharma, Researchers, CROs)
  • 2.3 Market Estimation
    • 2.3.1 Bottom-Up Approach
    • 2.3.2 Top-Down Approach
    • 2.3.3 Forecast Modeling
  • 2.4 Data Triangulation
  • 2.5 Assumptions

3. Executive Summary

4. Market Overview

  • 4.1 Introduction
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
      • 4.2.1.1 Growing Adoption of Personalized Cancer Immunotherapy
      • 4.2.1.2 Advancements in Genomics and Sequencing Technologies
      • 4.2.1.3 Increasing Cancer Incidence Globally
      • 4.2.1.4 Strong Pipeline of Neoantigen Vaccine Candidates
    • 4.2.2 Restraints
      • 4.2.2.1 High Cost of Personalized Vaccine Development
      • 4.2.2.2 Complex Manufacturing and Logistics
      • 4.2.2.3 Limited Commercial Approvals
    • 4.2.3 Opportunities
      • 4.2.3.1 Combination Therapies with Checkpoint Inhibitors
      • 4.2.3.2 Advances in AI-driven Neoantigen Prediction
      • 4.2.3.3 Expansion in mRNA Vaccine Platforms
      • 4.2.3.4 Growth in Clinical Trials
    • 4.2.4 Challenges
      • 4.2.4.1 Regulatory Complexity
      • 4.2.4.2 Variability in Patient-specific Responses
  • 4.3 Technology Landscape
    • 4.3.1 mRNA-based Neoantigen Vaccines
    • 4.3.2 Peptide-based Vaccines
    • 4.3.3 DNA-based Vaccines
    • 4.3.4 Viral Vector-based Vaccines
    • 4.3.5 Dendritic Cell-based Vaccines
    • 4.3.6 AI & Bioinformatics for Neoantigen Identification
  • 4.4 Neoantigen Vaccine Ecosystem
    • 4.4.1 Biopharmaceutical Companies
    • 4.4.2 Genomics & Sequencing Providers
    • 4.4.3 CROs & CDMOs
    • 4.4.4 Research Institutes
    • 4.4.5 Healthcare Providers
  • 4.5 Value Chain Analysis
    • 4.5.1 Tumor Sample Collection
    • 4.5.2 Genomic Sequencing & Analysis
    • 4.5.3 Neoantigen Identification & Selection
    • 4.5.4 Vaccine Design & Manufacturing
    • 4.5.5 Clinical Administration
  • 4.6 Regulatory Landscape
    • 4.6.1 FDA & EMA Guidelines
    • 4.6.2 Clinical Trial Regulations
    • 4.6.3 Personalized Medicine Regulatory Frameworks
  • 4.7 Industry Trends
    • 4.7.1 Rise of mRNA-based Cancer Vaccines
    • 4.7.2 Increasing Collaboration Between Pharma & Tech Firms
    • 4.7.3 Growth of Personalized Oncology
    • 4.7.7 Integration of AI in Vaccine Design
  • 4.8 Cost and Pricing Analysis
    • 4.8.1 Cost per Patient
    • 4.8.2 Manufacturing Cost Analysis
    • 4.8.3 Reimbursement Challenges

5. Neoantigen Cancer Vaccine Market, by Vaccine Type

  • 5.1 Introduction
  • 5.2 Personalized Neoantigen Vaccines
  • 5.3 Shared Neoantigen Vaccines

6. Neoantigen Cancer Vaccine Market, by Technology Platform

  • 6.1 mRNA-based Vaccines
  • 6.2 Peptide-based Vaccines
  • 6.3 DNA-based Vaccines
  • 6.4 Viral Vector-based Vaccines
  • 6.5 Dendritic Cell-based Vaccines

7. Neoantigen Cancer Vaccine Market, by Delivery Modality

  • 7.1 Injectable Vaccines
  • 7.2 Intradermal Delivery
  • 7.3 Other Delivery Methods

8. Neoantigen Cancer Vaccine Market, by Clinical Stage

  • 8.1 Preclinical
  • 8.2 Phase I
  • 8.3 Phase II
  • 8.4 Phase III

9. Neoantigen Cancer Vaccine Market, by Application

  • 9.1 Introduction
  • 9.2 Solid Tumors
    • 9.2.1 Lung Cancer
    • 9.2.2 Melanoma
    • 9.2.3 Breast Cancer
    • 9.2.4 Colorectal Cancer
    • 9.2.5 Other Solid Tumors
  • 9.3 Hematological Cancers
    • 9.3.1 Leukemia
    • 9.3.2 Lymphoma
    • 9.3.3 Multiple Myeloma
  • 9.4 Combination Therapies

10. Neoantigen Cancer Vaccine Market, by End User

  • 10.1 Hospitals & Cancer Treatment Centers
  • 10.2 Research Institutes
  • 10.3 Biopharmaceutical Companies

11. Neoantigen Cancer Vaccine Market, by Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 U.S.
    • 11.2.2 Canada
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 U.K.
    • 11.3.3 France
    • 11.3.4 Italy
    • 11.3.5 Spain
    • 11.3.6 Netherlands
    • 11.3.7 Sweden
    • 11.3.8 Switzerland
    • 11.3.9 Rest of Europe
  • 11.4 Asia-Pacific
    • 11.4.1 China
    • 11.4.2 Japan
    • 11.4.3 India
    • 11.4.4 South Korea
    • 11.4.5 Australia
    • 11.4.6 Singapore
    • 11.4.7 Rest of Asia-Pacific
  • 11.5 Latin America
    • 11.5.1 Brazil
    • 11.5.2 Mexico
    • 11.5.3 Rest of Latin America
  • 11.6 Middle East & Africa
    • 11.6.1 UAE
    • 11.6.2 Saudi Arabia
    • 11.6.3 South Africa
    • 11.6.4 Rest of MEA

12. Competitive Landscape

  • 12.1 Overview
  • 12.2 Key Growth Strategies
  • 12.3 Competitive Benchmarking
  • 12.4 Competitive Dashboard
    • 12.4.1 Industry Leaders
    • 12.4.2 Market Differentiators
    • 12.4.3 Emerging Players
  • 12.5 Market Ranking/Positioning Analysis

13. Company Profiles

  • 13.1 Moderna, Inc.
  • 13.2 BioNTech SE
  • 13.3 Genentech (Roche)
  • 13.4 Gritstone bio, Inc.
  • 13.5 Neon Therapeutics
  • 13.6 CureVac N.V.
  • 13.7 AstraZeneca plc
  • 13.8 Merck & Co., Inc.
  • 13.9 Pfizer Inc.
  • 13.10 Immatics N.V.
  • 13.11 ISA Pharmaceuticals B.V.
  • 13.12 Vaccibody AS
  • 13.13 Nouscom AG
  • 13.14 Genocea Biosciences
  • 13.15 Advaxis Inc.

14. Appendix

  • 14.1 Customization Options
  • 14.2 Related Reports